Research Vision

Mucosis strives to discover innovative mucosal vaccines that are more efficacious and user-friendly by translating excellent scientific research into a robust vaccine technology which we use to create better, painless and needle-free vaccines to combat viral, bacterial and parasitic pathogens. We are dedicated to achieving these goals by motivating talented researchers to excel and by collaborating with the best academic and industrial partners in the world.

research vision

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >

18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >